search icon
  • Print
  • ShareThis
  • Text Size
  • Management of Hepatitis C - Additional Information

    www.hep-druginteractions.org 
    An interactive chart to input HCV protease inhibitors, interferons and nucleoside/tide analogues to inform clinicians on drug-drug interactions.

    Hepatitis C Medications: Update on New Drugs
    Current information from the Department of Veterans Affairs on hepatitis C treatment drugs boceprevir and telaprevir. Criteria for use for each drug, provider and patient educational materials, and updated treatment guidelines are accessible at the VA Hepatitis C Medications site.

    Triple Therapy Workbooks
    The Department of Veterans Affairs offers two workbooks designed for patients to keep on hand throughout their treatment course with triple therapy-pegylated interferon, ribavirin, and a protease inhibitor (boceprevir or telaprevir).

    National Prevention Information Network (NPIN) Viral Hepatitis Headquarters
    The Centers for Disease Control and Prevention's NPIN provides clinicians with current information, resources, and tools to support efforts to prevent viral hepatitis.

    The Forum for Collaborative HIV Research

    Forum HCV Drug Resistance Slideset (ResisSS)
    The Forum for Collaborative HIV Research has developed four presentations explaining drug resistance in HCV, its consequences, and practices to minimize its impact.

    Clinically Relevant HCV Drug Resistance Mutations Figure and Tables (PDF) 
    A report on drug resistance information on direct-acting antivirals (DAAs) used to treat hepatitis C patients, concentrating on data from compounds which have entered phase 3 of clinical development or have been approved.

    HCV Drug Resistance (PDF)
    Viral resistance in HCV, concerns around HCV resistance, and prevention and how to overcome resistance to antiviral drugs.

    Forum for Collaborative HIV Research: Hepatitis C Project
    The Forum for Collaborative HIV Research's Hepatitis C Drug Development Advisory Group (DrAG) has developed an extensive pipeline of educational materials concerning hepatitis C drug issues such as development and resistance.

 

Average 0 out of 5

| HIVMA | Contact Us

© Copyright IDSA 2014 Infectious Diseases Society of America

Full Site Mobile Site